Background The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool-Binary Method (CAT-BM) have been shown to be reliable and valid outcome measures to assess cutaneous disease in adult dermatomyositis (DM) and juvenile DM (JDM), respectively. Objectives This study compared the CDASI and CAT-BM for use by paediatric dermatologists, paediatric rheumatologists and paediatric neurologists in patients with JDM. Methods Five paediatric dermatologists, five paediatric rheumatologists and five paediatric neurologists each evaluated 14 patients with JDM using the CDASI, CAT-BM, and skin Physician Global Assessment (PGA) scales. Inter-rater reliability, intra-rater reliability, construct validity and completion time were compared. Results Inter-rater reliability for CDASI activity and damage scores was good to moderate for paediatric dermatologists and rheumatologists, but poor for paediatric neurologists. The inter-rater reliability for CAT-BM activity scores was moderate for paediatric dermatologists and rheumatologists, but poor for paediatric neurologists and poor across all specialties for damage scores. Intra-rater reliability for the CDASI and CAT-BM activity and damage scores was moderate to excellent for paediatric dermatologists, rheumatologists and neurologists. Strong associations were found between skin PGA activity and damage scores and CDASI or CAT-BM activity and damage scores, respectively (P < 0Á002). The CDASI had a mean completion time of 5Á4 min compared with that for the CAT-BM of 3Á1 min.
Conclusions Our data confirm the reliability of the CDASI activity and damage scores and the CAT-BM activity scores when used by paediatric dermatologists and rheumatologists in assessing JDM. Significant variation existed in the paediatric neurologists' scores.
What's already known about this topic?
• The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) was developed by dermatologists as a reliable and valid outcome measure to assess cutaneous disease in adult dermatomyositis (DM).
• The Cutaneous Assessment Tool-Binary Method (CAT-BM) was similarly developed by paediatric rheumatologists for use in juvenile DM (JDM).
What does this study add?
• This study expands the application of the CDASI activity and damage scores for use in patients with JDM when performed by paediatric dermatologists and rheumatologists.
• This study also finds that CAT-BM activity scores are reliable when used by paediatric dermatologists and rheumatologists to assess skin findings in patients with JDM.
Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by specific cutaneous findings and proximal muscle weakness, along with potential pulmonary, gastrointestinal, cardiac and ocular involvement.
1,2 Among children, juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy, with an estimated incidence of between 2Á5 and 4Á1 cases per million. 3 Cutaneous manifestations of JDM precede or accompany the onset of muscle weakness in 76% of cases and are thought to be an important indicator of disease activity. [4] [5] [6] Indeed, studies have shown that skin manifestations, rather than muscle, tend to persist over time despite treatment. 7, 8 Additionally, current criteria for classifying patients with clinically inactive JDM underestimate the presence of skin activity in this population. 9 Multiple comprehensive instruments exist to assess JDM, including the Disease Assessment Scale (DAS) and the Myositis Disease Activity Assessment Tool. Of these, the DAS has been widely used to assess skin disease in the JDM population. This measure has been shown to have good construct validity and inter-rater reliability, although the skin-specific portion of the DAS demonstrates only moderate responsiveness to change. 10, 11 Currently there is only one existing validated tool, the Cutaneous Assessment Tool (CAT), that specifically assesses skin disease in JDM. [12] [13] [14] The CAT-Binary Method (CAT-BM) was developed as a shortened version of the CAT and dichotomizes the scoring of cutaneous features as present or absent. 15 It has been validated for use in JDM although no comparative studies among specialties other than paediatric rheumatology have been performed. [13] [14] [15] As a result, paediatric dermatologists and paediatric neurologists, who also treat patients with JDM and evaluate them in clinical trials, do not commonly use the CAT-BM to assess patients with JDM. In the past 10 years, the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) has been developed and validated for use in adult DM. 16, 17 The CDASI assesses skin activity and damage in 15 anatomical locations and assigns two scores, 0-100 for activity and 0-32 for damage, with higher scores indicating increased disease severity. A previous study has demonstrated that the CDASI has better responsiveness to clinical change when compared with other outcome measures for DM in adult patients, including the CAT-BM. 16 However, it is currently only validated for use in adult patients with DM. 16, 17 The purpose of the present study is twofold: firstly, to compare the abilities of paediatric physicians of various specialties to use the CDASI and CAT-BM in patients with JDM; and secondly, to compare the reliability of the two outcome measures relative to each other in this population.
Materials and methods
This study was approved by the University of Pennsylvania Institutional Review Board. Fifteen paediatric physicians and 14 patients with JDM were brought to the autoimmune skin disease clinic at the University of Pennsylvania on a single day in May 2015. All physicians first completed a 45-min training session on the assessment of cutaneous DM using three outcome measures: the CDASI, CAT-BM and skin Physician Global Assessment (PGA). The CDASI has previously been published; 18 the CAT-BM and the respective training modules for the CDASI and CAT-BM are available online at www.niehs.nih. gov/research/resources/imacs/othertools/index.cfm. Following the training, physicians individually rated each patient with JDM using each measure. Half of the assessments were performed with the CDASI before the CAT-BM, and the other half were performed with the CAT-BM before the CDASI; the skin PGA was assessed last. After completing all 14 assessments, physicians were instructed to reassess two available patients. At the end of the study activities, each physician completed a brief physician exit survey.
Physicians
Five paediatric dermatologists, five paediatric rheumatologists and five paediatric neurologists participated in this study. Of the dermatologists, four were attending-level, academic-based dermatologists, and one was completing a fellowship in paediatric dermatology. All completed or were in the process of receiving formal subspecialty training in paediatric dermatology at the time of the study with the exception of one dermatologist, who is a member of the Society for Pediatric Dermatology and an assistant professor of dermatology in paediatrics. Of the rheumatologists, four were attending-level, academic-based paediatric rheumatologists and one was a paediatric rheumatology fellow. Of the neurologists, two were attending-level, academic-based paediatric neurologists and three were postgraduate fifth-year paediatric neurology residents. Physicians were instructed to see patients based on availability with no order preassigned.
Skin Physician Global Assessment
The skin PGA is a physician-administered overall rating of skin disease severity. Assessments of skin activity, skin damage and global skin disease are each made on a 10-cm linear visual analogue scale (VAS) ranging from 0 (no evidence of disease) to 10 (extremely severe disease). As the skin PGA is a widely used global reference and benchmark in studies comparing outcome instruments in cutaneous DM, it was chosen in the present study to test construct validity. 16, 17 Assessment of inter-and intra-rater reliability Inter-rater reliability was assessed within each group of specialists. All physicians evaluated 14 patients during the study session, except one physician who evaluated 13 patients. To assess intra-rater reliability, all 14 physicians scored two patients twice. To minimize recall bias, physicians were not informed that they would need to reassess two patients until they had finished the initial assessment.
Statistical analysis
Previous studies have shown CDASI and CAT-BM scores to be normally distributed, so normality was assumed for this study. 17 Inter-rater reliability was estimated using the intraclass correlation coefficient (ICC), calculated from random-effect ANOVA models with patient-specific random effects. 19 If a patient was assessed twice by the same physician, only the first assessment was included in this analysis. In addition, for each physician group, the physician-specific ICC was estimated using the observations by each group of specialists. Previous studies have determined an ICC of 0Á50-0Á70 as moderate, 0Á70-0Á81 as good and > 0Á81 as almost perfect. 16, 17, 20 For this study, ICC scores of 0Á50-0Á70 were considered moderate and minimally acceptable, 0Á70-0Á81 good and > 0Á81 excellent. Any ICC scores < 0Á5 were considered poor. Intra-rater reliability of CDASI and CAT-BM activity and damage was estimated using the ICC, calculated from randomeffect ANOVA models. 19 The repeated CDASI and CAT-BM assessments from the same patients and same physician were included in the analysis. Two reads of the same patient by the same physician were considered to have the same normal distributions, that is, physician-patient combinations as random effects.
For the difference between paediatric dermatologists, neurologists and rheumatologists, the group means were estimated from the fixed effects in the same ANOVA models. The means in neurologists or rheumatologists were compared with the mean in dermatologists using t-tests within the ANOVA models with a significance level of 0Á025 (after adjusting for the number of comparisons). The time spent using the CDASI was summarized within each group of physicians and the differences from the dermatologists were tested using Dunnett's multiple comparisons in ANOVA. Only the first assessment from a physician on a patient was included in the analysis.
Construct validity was assessed by comparing the change in skin PGA activity with the per unit change in the CDASI and the CAT-BM activity scores and by comparing the change in skin PGA damage with the per unit change in the CDASI and the CAT-BM damage scores. P-values < 0Á05 were considered statistically significant for all analyses. The statistical analysis was carried out using R2.15.3 (www.R-project.org).
Results

Patients
Characteristics of the patient population are summarized in Table 1 .
Skin assessment scores among specialists
The mean skin assessment scores for the patients with JDM are presented in Table 2 . There was no difference between the mean CDASI activity scores of paediatric dermatologists and rheumatologists, although there was a significant difference between the paediatric dermatologists and neurologists. The mean CDASI damage scores differed between paediatric dermatologists and neurologists but not between paediatric dermatologists and rheumatologists.
As with the CDASI activity scores, there was a significant difference in the mean CAT-BM activity scores between paediatric dermatologists and neurologists but not between paediatric dermatologists and rheumatologists. Mean CAT-BM damage scores differed between paediatric dermatologists and neurologists and also between paediatric dermatologists and rheumatologists. There was no difference in mean skin PGA activity or damage scores between dermatologists and rheumatologists or between dermatologists and neurologists.
Twelve of 14 patients had mild activity, defined as a CDASI activity score ≤ 14. 21 The standard deviations of CDASI activity scores of patients with moderate to severe activity were not appreciably greater than the standard deviations of CDASI activity scores of patients with mild activity, suggesting that variance was not greater in patients with greater activity.
Inter-rater reliability
The CDASI was found to have moderate inter-rater reliability in activity scores among paediatric dermatologists, good interrater reliability among paediatric rheumatologists, and poor inter-rater reliability among paediatric neurologists (Table 3) . CDASI damage scores had moderate inter-rater reliability among paediatric dermatologists and rheumatologists and poor inter-rater reliability among paediatric neurologists. The CAT-BM activity scores had moderate inter-rater reliability among paediatric dermatologists and rheumatologists but poor inter-rater reliability among paediatric neurologists. The CAT-BM was found to have poor inter-rater reliability in damage scores across all three specialties.
The skin PGA activity scores had moderate inter-rater reliability among paediatric dermatologists, but poor inter-rater reliability among paediatric rheumatologists and neurologists. Skin PGA damage scores had good inter-rater reliability among paediatric dermatologists and neurologists, but poor inter-rater reliability among paediatric rheumatologists.
Intra-rater reliability
Intra-rater reliability was excellent among paediatric dermatologists and rheumatologists for the CDASI activity scores and moderate among paediatric neurologists (Table 4) . For CDASI damage, the intra-rater reliability was excellent among paediatric dermatologists, good among paediatric neurologists and moderate among paediatric rheumatologists.
Intra-rater reliability was excellent across all three specialties for CAT-BM activity scores. Damage scores for the CAT-BM were excellent for paediatric dermatologists and neurologists and good for paediatric rheumatologists.
The skin PGA activity and damage scores had excellent intra-rater reliability among paediatric dermatologists and Mean AE SD Mean AE SD P-value
Dermatologists were the reference standard. There was no difference between paediatric dermatologists and rheumatologists in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool-Binary Method (CAT-BM) activity, and skin Physician Global Assessment (PGA) scores, whereas there was a significant difference across CDASI and CAT-BM scores when evaluated by paediatric neurologists. Figures in bold indicate significant values. 1 Mean values by t-tests compared with paediatric dermatologists. All data are presented as n (%) unless otherwise stated. IQR, interquartile range.
neurologists, but only moderate intra-rater reliability among paediatric rheumatologists.
Outliers
Two outliers were noted. One paediatric neurologist consistently scored patients outside the group mean of paediatric neurologists, and one patient with JDM yielded scores that showed more variation than other patients. When these two individuals were removed, the paediatric neurologists' interobserver ICC for CDASI activity and damage scores improved from poor to moderate (ICC 0Á66 and 0Á61, respectively). The paediatric rheumatologists' interobserver ICC for CDASI activity also improved from good to excellent (ICC 0Á83). Although paediatric dermatologists' interobserver ICC for CDASI activity and damage scores stayed within the same moderate category, their activity and damage interobserver ICC scores for the CDASI also improved to ICC 0Á68 and 0Á63, respectively. Scores otherwise showed little change.
Construct validity
There were positive associations between the skin PGA activity and corresponding CDASI and CAT-BM activity scores as well as between the skin PGA damage and corresponding CDASI and CAT-BM damage scores. After adjusting for within-patient correlation and physician's difference, the CDASI activity score increased 0Á224 (P < 0Á001) and the CAT-BM activity score increased 0Á484 (P < 0Á001) for each unit increase in skin PGA activity. For each unit increase in skin PGA damage, the CDASI damage score increased 0Á343 (P < 0Á001) and the CAT-BM damage score increased 0Á256 (P = 0Á002).
Physician exit questionnaire
When asked how comfortable they felt using the CDASI, on a scale of 1-5 (1 = not comfortable at all; 5 = very comfortable), physicians responded with a mean score of 3Á8 among paediatric dermatologists, 3Á8 among paediatric rheumatologists and 3Á2 among paediatric neurologists. When asked how Table 3 Inter-rater reliability of skin assessment tool scores in patients with juvenile dermatomyositis among paediatric specialists Within paediatric dermatologists (n = 5)
Within paediatric rheumatologists (n = 5)
Within paediatric neurologists (n = 5)
All data are presented as intraclass correlation coefficients (95% confidence interval). The inter-rater agreement was moderate to good for paediatric rheumatologists and dermatologists using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool-Binary Method (CAT-BM) activity scores, whereas the inter-rater agreement was poor for paediatric neurologists using the same scores. PGA, Physician Global Assessment. Table 4 Intra-rater reliability of skin assessment tool scores in patients with juvenile dermatomyositis among paediatric specialists
Within paediatric dermatologists (n = 5)
All data are presented as intraclass correlation coefficients (95% confidence interval). The intra-rater agreement was excellent for paediatric dermatologists using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool-Binary Method (CAT-BM) measures, and the intra-rater agreement was good to excellent for paediatric rheumatologists and neurologists using the same outcome instruments. PGA, Physician Global Assessment.
comfortable they felt using the CAT-BM on the same scale, physicians responded with a mean score of 3Á6 among paediatric dermatologists, 3Á8 among paediatric rheumatologists and 3Á2 among paediatric neurologists.
Completion time
The CDASI had a mean completion time of 5Á4 min, with paediatric dermatologists averaging (mean AE SD) 5Á2 min AE 2Á8, paediatric rheumatologists averaging 4Á5 min AE 1Á4 and paediatric neurologists averaging 6Á5 min AE 3Á8. The CAT-BM had a mean completion time of 3Á1 min, with paediatric dermatologists averaging 2Á6 min AE 1Á7, paediatric rheumatologists averaging 2Á5 min AE 1Á2 and paediatric neurologists averaging 4Á1 min AE 3Á1.
Discussion
The CDASI was developed in order to provide an objective and reproducible outcome instrument to assess cutaneous manifestations of DM for use in clinical trials. 16, 17 Validation studies of the CDASI have established its face, content and construct validities, and comparisons of the CDASI with other outcome instruments including the CAT, have consistently demonstrated the superiority of the CDASI in inter-and intraobserver reliability in studies with adult DM patients. 16, 17 Most recently, the CDASI has been shown to yield good responsiveness, a key component of a valid outcome measure. 21 These studies have demonstrated the validity of the CDASI when used by dermatologists in the adult DM population. The CAT-BM, an outcome measure designed for the JDM population, was developed with goals similar to those of the CDASI. [13] [14] [15] Initial validation studies in the JDM population by paediatric rheumatologists demonstrated good construct validity and internal consistency; [13] [14] [15] subsequent studies in the adult DM population have confirmed its good construct and content validity along with moderate intra-rater reliability and responsiveness in the adult DM population. 16 Most recently, a study examining the CAT-BM in 71 patients with JDM found the CAT-BM to have poorer correlation with the VAS compared with the DAS, and poorer responsiveness than both the VAS and DAS. 11 However, previous work in the adult DM population has shown that the CDASI demonstrates better responsiveness than either the VAS or CAT-BM. 16 A comparative study of the CDASI and the CAT-BM in the JDM population has not yet been performed. The present study examines the reliability and validity of the CDASI and the CAT-BM in the JDM population when used by paediatric dermatologists, rheumatologists and neurologists. Among paediatric dermatologists and rheumatologists, the inter-rater reliability of the CDASI activity and damage scores ranged from moderate to very good. Similarly, the inter-rater reliability of CAT-BM activity scores was moderate among these specialists, although damage scores were poor. Intrarater reliability for both the CDASI and CAT-BM was generally excellent, and both demonstrated good construct validity. Mean scores between paediatric dermatologists and rheumatologists were generally similar for the CDASI and CAT-BM, and both outcome instruments were found to have comparable and short completion times. These findings support the use of the CDASI and CAT-BM by paediatric dermatologists and rheumatologists to assess skin activity in patients with JDM.
Of all the specialties involved in the study, the paediatric neurologists had the most difficulty with the outcome measures. Inter-rater reliability among paediatric neurologists was poor in the activity and damage scores of both the CAT-BM and the CDASI. The removal of the outlier paediatric neurologist improved the inter-rater reliability ICC for the CDASI activity and damage scores to moderate, although the presence of the outlier suggests that there is significant variation in the performance of the paediatric neurologists when using the CDASI. The group of neurologists included a greater number of trainees than did the other specialty groups; however, the outlier neurologist was an attending paediatric neuromuscular specialist, suggesting that trainee level did not affect performance. On the physician exit questionnaire, all five paediatric neurologists indicated that they felt they did not have enough training in assessing skin disease. The appropriate attribution of skin lesions remains a potential issue when using either the CDASI or the CAT-BM, and given that paediatric neurologists receive little training in assessing skin disease, this may present a challenge to paediatric neurologists when using the CDASI and/or CAT-BM in clinical research studies and trials.
Regardless of specialty, all of the participating physicians indicated on the exit questionnaire that they felt on average only somewhat comfortable when using either the CDASI or the CAT-BM. In particular, unclear terminology on the CAT-BM seemed to present an issue, while both instruments suffered from unclear scoring instructions, according to responses from the physician exit questionnaire. Given these responses, and the limited preparation prior to using the instruments, physicians who are expected to use the instruments would likely benefit from more extensive training before using either instrument.
We suggest that physicians with regular exposure to JDM are perhaps best suited to using these instruments. Paediatric rheumatologists outperformed all other specialties in the activity scores of both the CDASI and the CAT-BM. With the removal of one outlier patient, their interobserver ICC for the CDASI activity score reached 0Á83, considered to be excellent. Although one of the paediatric rheumatologists was involved in the development of the CAT-BM, none of the other physicians who performed assessments was involved in developing either instrument, suggesting that the paediatric rheumatologists' performance should not be attributed to prior experience with the instruments. We speculate that these results may be due to the reality that patients with JDM often receive primary management of their disease from paediatric rheumatologists as opposed to other specialists. However, any physician with sufficient experience in JDM is likely to use these outcome instruments adequately.
Limitations of the study include the relatively mild skin activity of the patients, which may underestimate the reliability of these outcome instruments. This study also did not include an evaluation of the DAS, which has recently demonstrated superior correlation with skin VAS than the CAT-BM, although with poorer responsiveness. 11 A direct comparison of the CDASI and DAS in the JDM population would be an informative future study.
In conclusion, the CDASI activity and damage scores demonstrate moderate to excellent reliability in patients with JDM when assessed by either paediatric rheumatologists or dermatologists. In contrast, the CAT-BM activity scores demonstrate moderate reliability among paediatric rheumatologists and dermatologists, while the CAT-BM damage scores are poor across all specialties. Both outcome measures show good construct validity with skin global activity. Physicians who plan to use these outcome measures may consider receiving formal training in the use of these instruments, but paediatric rheumatologists and dermatologists with experience in JDM may expect to use the CDASI and CAT-BM adequately. Previous studies in adult DM have shown increased responsiveness of the CDASI relative to the CAT-BM, potentially because the binary nature of the CAT-BM makes detection of anything other than complete resolution of skin activity difficult. 14, 20 Further studies of responsiveness of both measures applied to patients with JDM are needed to determine which outcome instrument, if any, is preferred.
